Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20188998 | 0.87 | KDM4E (0.48) | KDM4EMDM2ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL29834060 | 0.85 | KDM4E (0.47) | KDM4EMDM2ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL20187511 | 0.84 | CA1 (0.33) | KDM4EMDM2ALDH1A1SIGMAR1 | |
| SCHEMBL20187593 | 0.83 | BLM (0.35) | KDM4EMDM2ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL22069385 | 0.81 | SIGMAR1 (0.33) | KDM4EMDM2ALDH1A1SIGMAR1 | |
| SCHEMBL20187501 | 0.81 | ALDH1A1 (0.38) | KDM4EMDM2ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL20200024 | 0.80 | KDM4E (0.43) | KDM4EMDM2ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL22069474 | 0.79 | KMT2A (0.39) | KDM4EMDM2ALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL20191192 | 0.77 | ALDH1A1 (0.45) | KDM4EALDH1A1KMT2ASIGMAR1MEN1 | |
| SCHEMBL20187579 | 0.77 | ALDH1A1 (0.32) | ALDH1A1KMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814369-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-14 | — | — | US | claimed |
| US-20210221798-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-07-22 | — | — | US | claimed |
| US-11814369-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-11-14 | — | — | US | disclosed |
| US-20210221798-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-07-22 | — | — | US | disclosed |
| US-10975060-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-04-13 | — | — | US | disclosed |
| US-20200283420-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-09-10 | — | — | US | disclosed |
| EP-3544964-B1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | Bayer Pharma AG (DE) | 2020-06-17 | — | — | EP | disclosed |
| EP-3544964-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018096082-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283420-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | RXFP1, RXFP2, RXFP3 | KDM4E 1649/4885MDM2 4306/4885ALDH1A1 4666/4885 |
| US-11814369-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | RXFP1, RXFP2, RXFP3 | KDM4E 1649/4885MDM2 4306/4885ALDH1A1 4666/4885 |
| US-10975060-B2 | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | RXFP1, RXFP2, RXFP3 | KDM4E 1649/4885MDM2 4306/4885ALDH1A1 4666/4885 |
| US-20210221798-A1 | HIGH RELAXIVITY GADOLINIUM CHELATE COMPOUNDS FOR USE IN MAGNETIC RESONANCE IMAGING | RXFP1, RXFP2, RXFP3 | KDM4E 1649/4885MDM2 4306/4885ALDH1A1 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.